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Abstract. Neutropenia in the setting of acute hemato-
logical malignancies may impact disease prognosis, thus 
affecting therapy dose intensity. This is often due to 
chemotherapy-induced aplasia as well as to the disease itself. 
However, chronic neutropenia deserves further investigation, 
as the management of reversible concomitant causes may avoid 
treatment delay. The present study describes a case of an acute 
promyelocytic leukemia patient with chronic severe neutro-
penia of multifactorial origin, including acute leukemia itself, 
chemotherapy, autoimmune activation with anti-platelets and 
anti-neutrophil antibodies positivity, and the rare association 
of large granular lymphocyte (LGL) expansion. As neutro-
penia may challenge the diagnosis and treatment of acute 
malignancies, clinicians and hematopathologists must discuss 
the differential diagnosis in order to avoid misdiagnosing 
and undertreating concomitant diseases. In particular, LGL 
chronic expansion and autoimmunity should be considered.
Introduction
In patients undergoing chemotherapy for hematological malig-
nancies, neutropenia severity and duration are important tools 
to monitor bone marrow recovery, and may significantly affect 
the treatment dose intensity, with a possible impact on disease 
prognosis (1). In this setting, other causes of neutropenia may 
be difficult to diagnose, possibly leading to therapy delay 
and undertreatment. Chronic neutropenia, lasting >3 months, 
may be primary (idiopathic or autoimmune) or secondary to 
other conditions, including malignancies, chemicals or radia-
tion exposure (2). The present report describes a case of an 
acute promyelocytic leukemia (APL) patient who developed 
a long-lasting multifactorial neutropenia [associated with 
chemotherapy, autoimmunity and large granular lymphocyte 
(LGL) expansion], which was difficult to diagnose due to 
unusual disease association, and interfered with the leukemia 
treatment.
Case report
A 53-year-old male patient was referred to the outpatient 
service of Fondazione IRCCS Cà Granda, Ospedale Maggiore 
Policlinico (Milan, Italy) in March 2013 due to neutropenia 
[absolute neutrophil count (ANC), 1.1x103 cells/mm3; 
normal range, 1.5-6.5x103/mm3) and severe thrombocyto-
penia (18x103 cells/mm3; normal range, 130-400x103/mm3). 
The medical history was positive for rheumatic fever in his 
childhood, prostatic hypertrophy and chronic autoimmune 
thyroiditis. In 2004, the patient had been diagnosed with 
oligoastrocytoma and had been treated with chemotherapy 
(vincristine, procarbazine and lomustine), obtaining persistent 
remission. During this period, the patient had an oxcarbaz-
epine drug-induced neutropenia (1.2x103 cells/mm3), driven 
by epilepsy prophylaxis, which recovered upon substitution 
for levetiracetam. The patient's platelets and neutrophil levels 
during the follow-up are shown in Fig. 1. Physical examina-
tion at presentation revealed diffuse petechiae and an 8-cm 
diameter hematoma on the left gluteus. The liver (aspartate 
transaminase/alanine transaminase) and kidney (creatinine) 
values were normal, as well as the lactate dehydrogenase 
levels, coagulation times and fibrinogen; C reactive protein 
was increased (7.75 mg/dl; normal range, <0.5 mg/dl), while 
hepatitis B and C virus serology was negative. Anti-platelets 
autoantibodies were positive at low titer, suggesting primary 
immune thrombocytopenia. Thus, first‑line intravenous steroid 
therapy with methylprednisolone at 1 mg/kg/day was started, 
but after 7 days, the blood counts values further declined 
[hemoglobin (Hb), 10.7 g/dl; normal range, 13.5-17.5 g/dl; 
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neutrophils, 0.9x103 cells/mm3; and platelets, 19x103 cells/mm3], 
and the fibrinogen values started to decrease (99 mg/dl; 
normal range, 165-350 mg/dl). Bone marrow aspirate revealed 
40% infiltrate of myeloid blasts with immune phenotype and 
cytogenetics consistent with APL. Fresh frozen plasma and 
platelets transfusion were administered, as well as pathogenic 
therapy with all-trans retinoic acid (ATRA) and steroids. 
Polymerase chain reaction evaluation was positive for the 
promyelocytic leukemia protein/retinoic acid receptor α 
transcript, and induction chemotherapy with idarubicin 
(12 mg/m2) in addition to ATRA was therefore started. 
Induction was complicated by neutropenic fever of unknown 
origin, requiring antimicrobial broad-spectrum therapy 
and granulocyte-colony stimulating factor (G-CSF). At 
dischargement (April 15th, 2013), the blood counts had almost 
recovered (Hb, 10.2 g/dl; ANC, 1.17x103 cells/mm3; and 
platelets, 107x103 cells/mm3), and bone marrow evaluation 
revealed complete hematologic, morphologic, cytogenetic 
and molecular response. The first cycle of consolidation 
chemotherapy with idarubicin alongside ATRA was then 
administered. Due to prolonged moderate neutropenia (ANCs, 
0.74x103 cells/mm3 after 2 months), levetiracetam was tempo-
rary stopped, but no ANCs recovery was observed. In July 
2013, as a spontaneous increase in ANCs values occurred, a 
second chemotherapy consolidation course with ATRA and 
mitoxantrone was administered, which was complicated by 
severe febrile neutropenia (ANCs, 0.05x103 cells/mm3) and 
controlled by intravenous broad-spectrum antibiotics and 
G-CSF. However, in November 2013, severe neutropenia 
persisted, thus forcing consolidation chemotherapy interrup-
tion and maintenance with ATRA only. In January 2014, a mild 
lymphocytosis (absolute lymphocyte count, 6.5x103 cells/mm3) 
was observed. Peripheral blood flow cytometry demonstrated 
a cluster of differentiation (CD)3+ CD8+ CD57+ phenotype in 
99% of lymphocytes, consistent with T-LGL cells. However, 
no lymphocyte infiltrate was observed by bone marrow aspi-
rate and histology on April 2014, and computed tomography 
scan was negative for splenomegaly and lymphadenopathies. 
In addition, anti-neutrophils antibodies were positive by 
direct granulocyte immunofluorescence test and negative 
in serum. A year later, bone marrow histology revealed for 
the first time a 25% T-LGL infiltrate, consistent with T-LGL 
chronic lymphocytic disorder, according to the World Health 
Organization criteria (Fig. 2A) (3). From September 2013 to 
the time of writing this study, the clinical conditions of the 
patient remained stable, with moderate neutropenia and mild 
LGL lymphocytosis, without specific therapy (Fig. 1). A 
re-evaluation of the bone marrow histology sample obtained 
Figure 1. Patient absolute neutrophil counts (black line) and platelets (grey line) during the follow-up. Dotted arrow indicates all-trans retinoic acid treatment, 
including induction, consolidation and maintenance. Cross symbol represents grade 2 infections. ANC, absolute neutrophil counts; BM, bone marrow; APL, 
acute promyelocytic leukemia; LGL, large granular lymphocyte; PB, peripheral blood; ATRA, all-trans retinoic acid; PLT, platelet; I, induction chemotherapy; 
C, consolidation chemotherapy.
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at the time of APL diagnosis was positive for ~10% T-LGL 
infiltrate, which was missed at the first pathological evaluation 
(Fig. 2B).
The patient is presently in a good general condition. 
Complete remission has been maintained for acute promy-
elocytic leukemia for 21 months since the end of therapy, 
and the patient undergoes regular clinical check-ups every 
6 months. The patient provided written informed consent.
Discussion
The present study describes a case of three different causes 
of cytopenia in the same patient: Acute myeloid leukemia 
(AML), autoimmunity and LGL chronic expansion. In addi-
tion, a history of previous chemotherapy and the use of drugs 
possibly interfering with ANCs complicated the clinical 
setting.
LGL expansion presents with neutropenia in 70-80% 
of cases, and it has been reported in ≤35% of patients with 
idiopathic cytopenia of uncertain significance (4).
An association between LGL leukemia and solid or hema-
tological malignancies has been described in various series; 
in particular, chronic B-cell dyscrasia is often observed in 
LGL patients, including monoclonal gammopathy of undeter-
mined significance (MGUS), chronic lymphocytic leukemia, 
monoclonal B lymphocytosis, hairy cell leukemia and multiple 
myeloma (5). Additionally, LGL may be associated with 
myeloid malignancies such as myelodysplastic syndrome and 
myeloproliferative disease (6,7). However, to the best of our 
knowledge, the present study is the first report of an LGL/APL 
association in the same patient.
Considering the therapeutic approach, no killing was 
observed in LGL cells following APL chemotherapy; on the 
contrary, LGL clones continued to increase once the marrow 
leukemic blasts had been cleared. The prolonged neutropenia 
observed led to consolidation and maintenance therapy delay 
and modification. In particular, no methotrexate maintenance 
for APL was administered. Notably, methotrexate is also used 
in LGL, and it may have cleared LGL cells (5). In a recent 
report of six LGL/multiple myeloma cases, bortezomib-based 
therapy was able to inhibit LGL clones, whereas lenalidomide, 
which is known to activate T-natural killer cells, was ineffec-
tive (5,6).
In the present case, no LGL specific treatment was 
performed. Instead, a patient monitoring approach was 
preferred due to the potential side effects of immunosup-
pression both on infectious risk and cerebral tumors. 
Treatment is usually required in 30-70% of LGL patients due 
to cytopenia-related manifestations and/or organomegaly, 
B symptoms and LGL raising counts (7,8). Notably, all the 
infectious episodes observed in the present patient occurred 
during induction/consolidation, and were of grade ≤2.
Regarding possible pathogenic mechanisms, it has been 
hypothesized that clonal cytotoxic T-cell population could 
play a role in antitumor immunosurveillance by controlling 
concomitant neoplasia development, as observed in previous 
MGUS/LGL cases (5). Otherwise, LGL could derive from a 
‘proliferation escape’ following a chronic immune response 
against the concomitant tumor (9). It is difficult to assess 
whether LGL expansion is a primary or secondary event, and 
both conditions have been described (6). In the present patient, 
a posteriori evaluation of the bone marrow histology from 
the diagnosis of APL demonstrated that LGL expansion was 
already present, suggesting that it may have been an attempt 
to control APL tumor growth. Anti-APL chemotherapy and 
consequent promyelocytic lysis may have conferred a growing 
advantage, and may have ultimately led to a clone expansion 
of LGL cells. Of note, there was no peripheral blood lympho-
cytosis at that time, and a limited LGL clone is not easy to 
observe unless specific immunohistochemistry is performed. 
Consistently, bone marrow re-evaluation demonstrated a 
previously misdiagnosed LGL clone in patients with chronic 
idiopathic neutropenia, which subsequently evolved to LGL 
chronic expansion (2).
In the patient described in the present case report, 
anti-platelets and low titer anti-neutrophils antibodies were 
identified at different steps of the disease. Despite the low 
sensibility and specificity of the available tests, this may reflect 
an immune activation/dysregulation in the course of a hemato-
logical malignancy. Autoantibodies were previously observed 
to be positive in several patients, including those with AML. 
In particular, antinuclear antibody and anti-DNA positivity 
were detected in ≤90% in a study of 39 AML cases (10), and 
anti-cardiolipin antibodies were identified in 25 out of 37 
AML cases (68%) (11).
In conclusion, in the setting of acute malignancies, it is 
important to consider concomitant causes of unexplained 
persistent neutropenia. In particular, LGL chronic expansion 
Figure 2. (A) Bone marrow histology at large granular lymphocyte 
diagnosis: Increased CD3+ CD57+ lymphoid infiltrate, both interstitial 
and intra-sinusoidal, in the context of normally proliferating bone marrow, 
with cells at all differentiating stages. Magnification, x200. (B) Bone 
marrow histology at acute promyelocytic leukemia diagnosis: CD3+ CD57+ 
lymphoid infiltrate, both interstitial and intra-sinusoidal, in the context 
of CD13+ CD33+ CD38+ CD64+ CD117+ CD14- CD34- human leukocyte 
antigen-antigen D related- CD11a-b- promyelo-blast marrow invasion. 
Magnification, x100 (insert, x200). CD, cluster of differentiation.
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should be considered, and ad hoc immunohistochemistry 
should be performed. Furthermore, autoimmunity in the 
context of immune activation/dysregulation may contribute to 
the severity of neutropenia.
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